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Abstract 
Background:  Literature on the use of nicardipine, a dihydropyridine calcium channel 
antagonist, in children recovering from cardiac surgery is sparse and, to our knowledge, 
non-existent in children with single ventricle anatomy. We aimed to report our 
experience with nicardipine in these patient populations. 
Methods:  We performed a retrospective review of children recovering from aortic 
coarctectomy and superior cavopulmonary anastomoses who received nicardipine for 
hypertension at our institution between 2007-2013.  Hemodynamic variables prior to 
and after nicardipine initiation were compared using paired t-tests.  
Results:  Seven children recovering from aortic coarctectomy (median age 8.6 months, 
range: 1.5 months - 7.9 years) and four children recovering from superior 
cavopulmonary anastomosis (median age 7 months, range: 5 - 9 months) were 
reviewed.  For all patients, at 6 hours after initiation of nicardipine, mean systolic blood 
pressure was significantly decreased, 123 ± 19 mmHg versus 103 ± 14 mmHg 
(P=0.001), as were diastolic blood pressure, 68 ± 20 mmHg versus 53.5 ± 10 mmHg 
(P=0.041), and sodium nitroprusside dose, 4.3 ± 2.9 mcg/kg/min versus 1.3 ± 1.7 
mcg/kg/min (P=0.002).   Further, within 24 hours, serum lactate decreased from 1.45 ± 
0.82 mg/dL to 0.81 ± 0.29 mg/dL (P=0.016).  Heart rate, blood urea nitrogen and serum 
creatinine measurements were statistically unchanged.   
Conclusions:  Nicardipine effectively decreased blood pressure without apparent 
adverse events in a small cohort of children with postoperative hypertension while 
recovering from aortic coarctectomy and superior cavopulmonary anastomosis.  Further 
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research comparing nicardipine to more conventional titratable anti-hypertensive agents 
in these patient populations is warranted. 
Abstract Word Count:  249 
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Introduction 
Hypertension is a relatively common complication following surgery for congenital heart 
disease, especially in the immediate postoperative period, for patients recovering from 
aortic coarctectomy (1-2) and superior cavopulmonary anastomoses (3-4).  For these 
children, titratable intravenous anti-hypertensive medications are the mainstays of 
therapy.  Sodium nitroprusside and esmolol are most commonly implemented and most 
extensively studied (5-6). Both of these agents however have potential undesirable side 
effects.  Sodium nitroprusside is a nitric oxide donor that is quickly metabolized in vivo 
to cyanide and thiocyanate, both of which have been shown to accumulate with 
standard dose infusions (7-8).  Additionally, sodium nitroprusside is a potent venodilator 
that often requires volume loading to maintain adequate cardiac preload.   Esmolol, a 
beta-adrenergic antagonist, could cause acute myocardial depression or exacerbate 
underlying reactive airway disease.  Perhaps most importantly, in some cases, 
hypertension will persist despite implementation of one or both of these agents.  For 
these reasons, alternative titratable agents should be explored.    
We aimed to report our experience using nicardipine, a dihydropyridine calcium channel 
antagonist, for hypertension in infants and children recovering from aortic coarctectomy 
and superior cavopulmonary anastomoses.  We hypothesized that a review of our 
experience would demonstrate nicardipine to be an effective agent in these patient 
populations without apparent unwanted clinical effects.      
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Patients and Methods 
This retrospective study was approved by the Institutional Review Boards at Wayne 
State University and the Detroit Medical Center.  Due to the retrospective nature of the 
study, the need for informed consent was waived.  All children who received nicardipine 
for hypertension following aortic coarctectomy and superior cavopulmonary 
anastomosis at our institution from 2007-2013 were reviewed.  Patient characteristics 
such as age at surgery, underlying cardiac diagnosis, and durations of cardiopulmonary 
bypass and aortic cross-clamping were recorded.  Hemodynamic parameters (e.g. 
systolic and diastolic pressure, heart rate), dose of sodium nitroprusside infusion, and 
dose of esmolol immediately prior to nicardipine initiation and six hours after initiation of 
the infusion were recorded.  Arterial lactate, blood urea nitrogen (BUN), and creatinine 
measurements prior to and during the 24 hours subsequent to nicardipine initiation were 
also recorded. 
Data are provided as mean with standard deviation for normally-distributed continuous 
variables and median with range for skewed continuous variables.  Data before and 
after initiation of nicardipine infusion were compared using paired student t-tests 
Results 
Eleven patients who received nicardipine for hypertension following pediatric cardiac 
surgery were identified and reviewed.  Four of the patients were infants with single 
ventricle anatomy recovering from their superior cavopulmonary anastomoses and 
seven patients were children with coarctation of the aorta who had undergone aortic 
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coarctectomy.  These patients are summarized in Table 1.  Median ages of children 
undergoing superior cavopulmonary anastomoses and coarctectomy were 7 months 
(range: 5 months - 9 months) 8.6 months (range: 1.5 months - 7.9 years), respectively.  
Transesophageal echocardiograms performed intraoperatively following 
cardiopulmonary bypass were available for the four study patients who underwent 
superior cavopulmonary anastomoses and reported normal single ventricle function. 
All patients were receiving sodium nitroprusside, esmolol, or both for postoperative 
hypertension at the time of nicardipine initiation.  Median timing of nicardipine initiation 
for all patients was postoperative day 1 (range: 0 - 6).  Initial nicardipine dose was 0.5 
mcg/kg/min in all patients, and the median maximum nicardipine dose used was 2.75 
mcg/kg/min (range: 1 - 5 mcg/kg/min).  Median duration of nicardipine infusion was 33 
hours (range: 12 - 96 hours).  Mean systolic and diastolic blood pressure, heart rate, 
nitroprusside and esmolol dose, arterial lactate, BUN and creatinine before initiation of 
nicardipine infusion and after nicardipine infusion are provided in Table 2.  Mean 
systolic and diastolic blood pressure, and sodium nitroprusside dose were significantly 
decreased within 6 hours of nicardipine infusion while mean heart rate was relatively 
unchanged.  Within 24 hours, arterial lactate was significantly decreased, and mean 
BUN and creatinine values were statistically unchanged from pre-infusion 
measurements.  Changes in systolic blood pressure immediately before and six hours 
after initiation of nicardipine infusion for individual patients are illustrated in Figure 1.  
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Discussion 
Hypertension following aortic coarctectomy has been well-described (1-2).  The 
pathophysiology of this hypertension is multi-factorial though has been primarily 
ascribed to alterations in baroreceptor stimulation leading to excessive sympathetic 
nervous system activity (2).  In our patients, nicardipine not only effectively reduced 
systolic and diastolic blood pressure but also permitted, in many cases, weaning of 
sodium nitroprusside and esmolol infusions.  Use of an arteriolar vasodilator such as 
nicardipine should be physiologically appropriate for these patients, considering 
excessive sympathetic nervous system activity predominantly leads to release of the 
potent vasoconstrictor norepinephrine and stimulation of the renin-angiotensin-
aldosterone axis.  In addition to our experience, use of nicardipine after aortic 
coarctectomy has been reported in three other small case series.  In 1993, Treluyer et 
al provided the first report of nicardipine hypertension in pediatric patients, a case series 
of 14 children, 5 of which were cardiac patients recovering from aortic coartectomy (9).   
In 2001, Tobias published the first report of nicardipine use exclusive to children 
recovering from cardiac surgery.  This series contained 9 patients, all with two ventricle 
anatomy, and 3 of which had underwent aortic coarctectomy (10).  In 2004, Nakagawa 
and colleagues published the first, and to our knowledge, only study devoted exclusively 
to the use of nicardipine in patients recovering from aortic coarctectomy, N=10 (11).  In 
all of these reports, nicardipine was effective at lowering blood pressure without any 
detectable clinical side effects.  Yet despite a sound physiologic rationale for its use and 
encouraging early observational experiences, no further research focused on 
nicardipine use in this patient population, to our knowledge, has been published.   
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Hypertension while recovering from superior cavopulmonary anastomoses has also 
been previously reported (3-4).  The pathophysiology of hypertension in these patients 
has been postulated to primarily be a compensatory response to increased cerebral 
systemic venous pressures.  Sodium nitroprusside has most commonly been reported 
as a first line agent in these patients.  In an elegant study by Simsic et al, they 
demonstrated that reduction of arterial blood pressure using sodium nitroprusside did 
not alter cerebral autoregulation and thus did not adversely affect cerebral blood flow.  
On the other hand, adequate systemic venous pressure is required to maintain passive 
pulmonary blood flow in these patients, which could theoretically be adversely affected 
by a potent venodilator such as sodium nitroprusside.  Nicardipine, which has little effect 
on systemic venous resistance (12), could offer a theoretical advantage to these 
patients.  To our knowledge, this report is the first description of the use of nicardipine in 
infants with single ventricle anatomy.    
 
Use of calcium-channel antagonists in infants and young children, especially those with 
cardiac disease, has historically been discouraged, in large part because of differences 
between the immature and adult myocardium.  The neonatal myocardium has been 
shown to have a lower density of calcium channels (13) and reduced intracellular stores 
of calcium secondary to an underdeveloped T-tubule network (14).  Consequently, the 
neonatal myocardium depends more so on extracellular calcium and is more sensitive 
to calcium channel blockade.  For example, verapamil, a non-dihydropyridine calcium-
channel antagonist, has been associated with cardiovascular collapse in neonates and 
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infants, even at therapeutic doses, and thus relatively contraindicated in this age group 
(15), though this notion has recently been questioned (16).  Nicardipine, in contrast to 
verapamil and other non-dihydropyridine calcium channel antagonists, has greater 
selectivity for L-type calcium channels in vascular smooth muscle than in cardiac 
myocytes (12). This selectivity is related to the voltage-dependence of L-type calcium 
channels, such that the resting membrane potential of vascular smooth muscle cells is 
less negative than that of cardiac myocytes.  As a result, nicardipine should have 
minimal effect on myocardial function.  In fact, studies of nicardipine use in adults with 
myocardial dysfunction have demonstrated increased in cardiac index, decreased 
pulmonary capillary wedge pressure, and improved coronary blood flow (12).  In our 
series, none of the patients, which includes 6 patients who were also receiving esmolol 
infusions at the time of nicardipine initiation, experienced hypotension, bradycardia, or 
signs of hypoperfusion while receiving nicardipine infusions.  These data should 
encourage further investigation into the use of nicardipine in these children. 
This study represents retrospective pilot data from a small single center case series.  
Nicardipine use in infants and children after cardiac surgery must be further studied 
before more widespread use can be recommended.  Pharmacokinetic data are needed 
in this patient population in order to optimize dosing regimens.  Moreover, studies 
comparing the efficacy and safety of nicardipine to sodium nitroprusside or esmolol 
following aortic coarctectomy or superior cavopulmonary anastomoses should be 
pursued.  A multi-centered study randomizing infants with postoperative hypertension 
while recovering from these cardiac surgeries to one of these three agents would be 
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particularly helpful to the pediatric cardiac critical care community.  With additional 
research, nicardipine could become an important part of the limited armamentarium of 
vasoactive medications available to cardiac intensive care providers. 
Conclusions 
In a small cohort of patients with biventricular and univentricular anatomy, nicardipine 
effectively reduced blood pressure without apparent adverse events in patients with 
hypertension after pediatric cardiac surgery.  
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Table 1.  Hemodynamic measurements and vasoactive medication doses before 
nicardipine infusion 
Cardiac 
Lesion 
Age 
(months) 
SBP 
(mmHg) 
DBP 
(mmHg) 
HR 
(bpm) 
Nitroprusside 
(mcg/kg/min) 
Esmolol 
(mcg/kg/min) 
PA/IVS 8 133 81 132 4 0 
HLHS 5 126 62 131 2 0 
HLHS 6 98 40 100 7 0 
HLHS 9 134 86 156 5 0 
CoA 1 116 72 138 6 250 
CoA 2 116 52 118 0 350 
CoA 2 108 65 137 6 300 
CoA 8 108 64 130 4 400 
CoA 50 168 110 113 10 0 
CoA 52 131 74 107 1 250 
CoA 94 118 42 135 2 50 
a PA/IVS: pulmonary atresia with intact ventricular septum; HLHS: hypoplastic left heart syndrome; CoA: 
coarctation of the aorta; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate 
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Table 2. Mean changes in hemodynamic variables before and after nicardipine 
initiation 
Variablea Pre-nicardipine Post-nicardipine P-value 
Systolic BP (mmHg) 120 ± 5.8 101 ± 4.5 0.014 
Diastolic BP (mmHg) 66 ± 5.8 53 ± 2.9 0.049 
Heart Rate (bpm) 129.5 ± 5 125.5 ± 4.6 0.57 
Nitroprusside (mcg/kg/min) 3.9 ± 0.9 1.2 ± 0.5 0.012 
Esmolol (mcg/kg/min)b 225 ± 195 221 ± 149 0.89 
Arterial lactate (mg/dL) 1.52 ± 0.25 0.87 ± 0.11 0.034 
BUN (mg/dL) 13.9 ± 5.5 13 ± 6.3 0.72 
Creatinine (mg/dL) 0.45 ± 0.15 0.43 ± 0.2 0.81 
a Hemodynamic parameters and vasoactive medication doses represent values immediately prior to and 
six hours post-initiation of the infusion.  Arterial lactate, blood urea nitrogen (BUN), and creatinine 
represent measurements prior to and during the 24 hours subsequent to initiation of the infusion. 
b Contains measurements from only patients recovering from aortic coartectomy (n=7); no patients 
recovering from superior cavopulmonary anastomoses received esmolol. 
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Figure Legends 
Figure 1.  Changes in systolic blood pressure (BP) in patients recovering from aortic 
coarctectomy (black lines) and superior cavopulmonary anastomoses (gray lines) six 
hours after initiation of nicardipine infusion.  Systolic BP was decreased in all but one 
post-coartectomy patient, in whom esmolol was aggressively weaned from 350 to 100 
mcg/kg/min during this time period.  Mean change in systolic BP was –15.5 ± 9.9%. 
